Dana-Farber Cancer Institute (Dana-Farber) and Beth Israel Deaconess Medical Center announced plans for a comprehensive new collaboration designed to advance the future of cancer care and build the region’s only independent, freestanding inpatient hospital for adult cancer patients in Boston, Massachusetts.
The hospital will increase adult patient capacity and create flexibility to incorporate the innovations and technology in cancer care that Dana-Farber’s and BIDMC’s researchers and clinicians are developing. Located adjacent to existing Dana-Farber and BIDMC facilities in Boston’s Longwood Medical Area, the proposed new cancer hospital will support both seamless patient care and continued focus on research initiatives.
While each organization will remain fully independent, the collaboration leverages the expertise of both institutions. The proposed inpatient cancer hospital will operate under the license of Dana-Farber and provide adult medical oncology care. Dana-Farber and BIDMC, with its affiliated physician group, Harvard Medical Faculty Physicians, will establish a coordinated clinical and organizational structure for oncology care in the Longwood Medical Area of Boston.
Pending regulatory approvals, it will take several years to implement the cancer collaboration and construct the new hospital. Dana-Farber’s affiliation with Brigham and Women’s Hospital for inpatient and surgical care will continue through the transition. BIDMC’s independent oncology programs will also continue until the new collaboration is in place. Outpatient oncology care at Dana-Farber’s existing locations in Boston, Chestnut Hill and other regional campuses will not be interrupted.
